Where these injections fit in your joint-care plan

A common crossroads comes after a first “quick fix” has worn off: for example, a person with knee osteoarthritis who felt better for a few weeks after a cortisone shot, then sees clinics advertising “exosomes” as a newer, stronger alternative, while someone else with a focal ankle cartilage defect is offered bone marrow aspirate concentrate (BMAC) alongside joint-preserving treatment. These options are not interchangeable, even though they are all discussed as injection-based approaches.

To keep the comparisons apples-to-apples, the clearest way is to think of steroids and exosomes mainly in knee osteoarthritis, and BMAC mainly in ankle cartilage defects (osteochondral lesions of the talus)—because that’s where the most direct evidence clusters (including a 2025 narrative review for ankle OA and an ongoing knee exosome trial: NCT06431152).

• Repeat corticosteroid injections (hip/knee pain): best understood as a short-term anti-inflammatory pain-relief tool. In a 2024 meta-analysis (11 RCTs; 842 people), benefits were clinically meaningful at about 6 weeks, faded by 6–12 weeks, and were not better than placebo at 6 months. In a 140-patient trial using triamcinolone 40 mg every 3 months for 2 years, MRI showed greater cartilage volume loss than saline, with no sustained pain advantage.
• BMAC (ankle cartilage defects/ankle OA): aims to support repair biology, but the evidence in talar lesions is limited: one systematic review found only four small studies (no randomised trials) and described an “overwhelming paucity” of high-level data. A 2025 narrative review notes BMAC is often used as an adjunct (making its independent effect hard to isolate) and calls for standardised protocols and RCTs.
• Exosomes (knee OA): a highly experimental signalling-based biologic. The FDA states there are no FDA-approved exosome products and has issued safety alerts describing serious adverse events from unapproved products; legitimate clinical use is expected to sit within regulated research (for example, under a registered study such as NCT06431152).

Across these choices, the practical decision tends to centre on a small set of questions: whether the primary goal is rapid symptom control versus joint preservation, how much uncertainty is acceptable (for example, “experimental” trials versus established symptomatic care), and how heavily factors like evidence strength, added procedures (such as marrow harvest), cost, and regulatory status should weigh in the balance.

Exosome injections for knee arthritis are still experimental

Regulation is the first reality check with exosome injections. The US Food and Drug Administration (FDA) has issued public safety communications stating that there are currently no FDA‑approved exosome products and that exosomes promoted to treat diseases are generally regulated as drugs/biological products that require formal pre‑market review and approval. The same FDA alert describes clinics marketing exosome injections outside this framework and notes reports of serious adverse events linked to unapproved products—one reason regulators emphasise avoiding “off‑menu” exosome treatments marketed as routine care. In the UK, comparable principles apply: any biologic presented as a treatment is expected to sit within appropriate medicines regulation and clinical governance rather than being sold as a standard “wellness” add‑on.

The scientific rationale is real, but it is still mostly laboratory and animal work. Exosomes are tiny packages released by cells (often mesenchymal stromal/stem cells) that carry signalling molecules. In a 2024 osteoarthritis paper using a rat model, tailored mesenchymal stem cell–derived exosomes were reported to dampen inflammation and support cartilage repair processes. Separately, a 2024 study exploring hydrogel microcarriers described exosome delivery strategies intended to improve cartilage repair performance in experimental osteoarthritis systems. These findings support biological plausibility, but they do not yet answer the practical clinical questions that matter in knee osteoarthritis—how much pain and function improves in people, for how long, and with what side‑effects at a defined dose and preparation.

Human evidence remains early‑stage and largely safety‑led. For example, ClinicalTrials.gov study NCT06431152 is evaluating the safety of injecting small extracellular vesicles (exosomes) derived from allogeneic mesenchymal stromal cells into the knee. The existence of trials like NCT06431152 underlines that exosome injections for knee osteoarthritis are still being tested rather than established as standard care.

Instead of a long checklist, credibility often shows up as a few clear signals:

• Green flags: the provider can point to a registered study (for example, a ClinicalTrials.gov or ISRCTN record) and talks mainly about safety monitoring and predefined outcomes; the FDA specifically advises confirming the product is being used under an FDA‑reviewed Investigational New Drug (IND) application and requesting the IND number.
• Red flags: reliance on testimonials, claims that exosomes are “exempt” from medicines regulation, or promises of cartilage “regrowth” without trial documentation.

Key uncertainties are still open: the best dose, how preparations are standardised, how many injections (if any) are needed, and whether any benefit is durable. Long‑term safety is also not settled—particularly the possibility of unexpected immune effects or other adverse biological responses—because properly controlled studies with longer follow‑up are still in progress.

BMAC injections for ankle cartilage defects

Bone marrow aspirate concentrate (BMAC) is an autologous orthobiologic: bone marrow is drawn from the iliac crest (pelvis) through a needle, processed in a centrifuge to concentrate a mix of cells and signalling proteins, and then placed back into the ankle region. In day-to-day terms, it is intended to support the body’s own repair biology around a cartilage or bone-cartilage injury rather than act like a simple anti-inflammatory painkiller injection.

For osteochondral lesions of the talus (OLT)—a focal defect on the top of the ankle bone—the way BMAC is used in published techniques is often more involved than “one quick shot”. A commonly described pathway is: clinic assessment and imaging to confirm a focal lesion; then, on the treatment day, marrow harvest from the ipsilateral iliac crest, concentration of the aspirate, and guided placement of BMAC into the prepared defect, sometimes mixed with fibrin glue, with the ankle positioned to allow access to the lesion. One technical description of OLT treatment sets this out as microfracture plus BMAC augmentation, with BMAC applied into the defect after preparation under ankle distraction (a surgical environment rather than a standard injection appointment).

That “augmentation” point matters. In ankle cartilage defects, BMAC is most often discussed as an add-on layered onto established joint-preserving procedures (for example microfracture) rather than a stand-alone first-line injection for ankle pain. Even when clinicians place BMAC into the ankle joint space under image guidance (ultrasound or fluoroscopy), the rationale is usually to complement a wider plan for a focal, potentially repairable lesion.

The evidence base remains limited. A systematic review of BMAC for talar osteochondral lesions found only four small studies (three retrospective case series and one prospective cohort), with no randomised trials and limited long-term follow-up; most reports described symptom improvement, but the review concluded there was an “overwhelming paucity” of high-level evidence and urged careful use while indications and target groups are better defined.

Broader reviews have landed in a similar place. A 2025 narrative review of BMAC in ankle osteoarthritis reports that BMAC may support cartilage repair—particularly when combined with other surgical and biologic techniques—but emphasises that most published evidence is level II–IV and commonly uses BMAC as an adjunct, making its independent contribution hard to isolate. A separate foot-and-ankle review also suggests any benefit in OLT may be most noticeable early on, with final repair tissue often described as fibrocartilage, and it highlights practical trade-offs such as added cost and donor-site morbidity from iliac crest harvest.

Takeaway: in ankle cartilage defects, BMAC is usually not a simple one-off injection; it is typically an adjunct to a joint-preserving procedure, and the studies so far are too small to show clearly how much extra benefit BMAC adds on its own.

In consultation discussions, the deciding factors often include the size and location of the talar lesion on MRI, what the clinician expects BMAC to add in that specific pathway, and the downside profile—particularly pelvic harvest soreness, the likelihood of needing further treatment if symptoms persist, and how BMAC compares with other joint-preserving options used for OLT in that service.

Repeat steroid injections for hip and knee pain

For many hip and knee arthritis flares, the attraction of an intra‑articular corticosteroid injection is that it can settle pain relatively quickly (often within a few days) and can create a “window” to re-engage with rehab, walking tolerance, and sleep while longer-term measures are being optimised.

The trade-off is duration. A 2024 systematic review and meta‑analysis pooling 11 randomised trials (842 people) found the clearest, clinically meaningful improvement versus placebo was in the short term (up to about 6 weeks). Benefits then tended to fade over the following weeks, with no clear advantage over placebo by 6 months or later. That pattern is one reason steroid injections are usually framed as symptom control rather than a disease‑modifying treatment.

In practice, many clinicians treat the quality of the response as the main guide to whether a repeat injection is worth considering. A “repeatable” response is typically recorded as: a clear drop in pain, a noticeable functional gain (for example, stairs or longer walks), and relief that lasts long enough to change day‑to‑day activity over several weeks rather than a few days. When the benefit shrinks to a brief or marginal effect, the next decision often shifts towards alternatives rather than “topping up” on the same cycle.

Caution increases when repeats become frequent and long-term. In a double‑blind randomised trial of 140 patients with knee osteoarthritis, triamcinolone 40 mg given every 3 months for 2 years resulted in greater cartilage volume loss on MRI than saline injections, without better pain outcomes over those 2 years. This does not prove that an occasional, well‑spaced injection is harmful in every case, but it does support avoiding a default pattern of 3‑monthly injections over years.

Repeat exposure also matters because corticosteroids have whole‑body effects. NHS information notes that the likelihood and severity of adverse effects rise with higher doses and longer duration of steroid exposure; listed concerns include osteoporosis (bone thinning), increased infection risk, mood or psychiatric changes, Cushingoid features/weight gain, raised blood sugar/diabetes, hypertension, and eye problems such as glaucoma or cataracts. These risks tend to carry extra weight in people with diabetes, established osteoporosis, or recurrent infections.

There is no single, evidence-based lifetime limit for hip or knee injections. Instead, expert guidance tends to use pragmatic spacing and frequency limits per joint, aiming to balance short‑term benefit against the combination of diminishing returns and cumulative risk; an expert consensus for knee osteoarthritis, for example, published 22 recommendations on indications, timing, dosing frequency, and contraindications.

Common “stop or pause” triggers that appear in clinic decision-making include:

• A documented pattern of diminishing benefit after one or more repeats (for example, relief no longer lasting beyond a few weeks).
• A plan point where surgery is being actively considered, and short-lived symptom relief is no longer the priority.
• Systemic vulnerability becoming more important than symptom gain (for example, significant post‑injection blood sugar rises in diabetes, or infection risk concerns noted in the medical record).
• A shift in goals towards longer‑acting options (such as PRP in some knee OA studies) rather than another short cycle of steroid relief.

Balancing biologic options against more steroid injections

Once steroid injections have been tried more than once—often after 2 rounds where relief is shorter or less predictable—the next discussion tends to be less about finding “a stronger shot” and more about choosing a strategy that matches the underlying problem (flare control versus joint preservation) and the level of uncertainty that feels acceptable. Rather than repeating the trial headlines already covered, the trade-offs can be organised into a few practical decision axes.

A simple way to compare options: four decision axes

Goal and time horizon (weeks versus years): corticosteroid injections are mainly used for short-term symptom control, whereas biologic options are usually positioned as attempts to support function and joint health over a longer period, alongside rehab.

Evidence maturity (human outcomes versus promising mechanisms): knee steroid injections have multiple randomised trials (including a widely cited 2017 MRI study raising structural concerns with frequent long-term repeat dosing), while exosome injections sit at the early research end, with mechanistic animal data but limited completed human outcome evidence and ongoing safety-focused work (for example NCT06431152). BMAC for ankle cartilage problems has published clinical reports, but the ankle literature remains largely small and non-randomised, including a systematic review limited to 4 studies and a 2025 narrative review calling for standardised protocols and randomised comparisons.

Treatment burden (simple injection versus harvest/adjunct procedure): BMAC usually involves an iliac-crest marrow harvest and is commonly used as an adjunct in ankle cartilage pathways, rather than as a simple “swap” for a knee steroid injection.

Governance and transparency (routine care versus research/marketed add-ons): the FDA has issued public alerts about unapproved exosome products and specifically advises checking for formal oversight (such as an IND in the US research setting) when exosomes are offered as treatment.

“Middle-ground” injectables often discussed when steroids wear off

In knee osteoarthritis, a common next step discussed in clinics is PRP rather than jumping straight to exosomes: a 2025 systematic review of randomised trials comparing PRP with corticosteroids reported that both were generally safe and improved symptoms, with several trials suggesting PRP effects may last longer than steroid effects. Other non-biologic or longer-acting injectables used in practice (such as hyaluronic acid or polyacrylamide hydrogel products) are also part of this “between steroids and highly experimental” space, depending on joint stage and clinician preference.

Scenario prompts that change the direction of the conversation

• Focal ankle cartilage defect (talar OLT) on imaging: BMAC may be raised as an add-on within a broader joint-preserving plan, but published evidence remains low-level and the independent benefit over the base procedure is still unclear.
• Knee osteoarthritis after several short-lived steroid responses: the emphasis often shifts to structured rehab plus an injectable with a more durable intent (commonly PRP), or to escalation pathways such as surgical opinions, rather than repeating the same steroid cycle.
• Exosomes marketed for “knee regeneration”: the key differentiator is whether the offer is genuinely within regulated research (for example a registered trial) versus a commercial product sold outside established approval routes.

Questions that commonly anchor a balanced comparison include: “What is the expected duration of benefit in this joint stage?”, “What is the downside profile (including harvest-site effects for BMAC)?”, “What evidence exists beyond animal data?”, and “What is the full self-pay cost versus the alternative plan over 12 months?”

Questions to ask and finding a suitable specialist

Some consultations are decided by what gets measured and written down on the day (for example, a baseline pain score, a specific MRI finding, or a plan to review at 6–12 weeks), so it helps to bring a short, structured set of questions.

Questions that apply to any joint injection

• What is the main goal in this joint now (short-term flare control, diagnostic clarity, or longer-term function)?
• What evidence supports this option in my specific diagnosis (for example, knee osteoarthritis versus a focal talar OLT)—and what is still uncertain?
• What is the expected time course: when should improvement start, and when is it considered “not working” (for example, by 6 weeks) ?
• What are the main risks in this joint and for my medical history (for example, diabetes or osteoporosis) and how will they be mitigated?
• How many of these has the clinician performed in the last 12 months, and what alternatives would be reasonable if this fails?

Extra questions about exosomes (knee osteoarthritis)

• The FDA states there are currently no FDA‑approved exosome products: what exactly is being injected, and what regulatory status is being claimed?
• Is the product being used under formal oversight (for example, an FDA‑reviewed IND if the clinic references US governance), and can the documentation/IND number be provided?
• What human evidence exists in knee osteoarthritis (not just lab/animal work), and what safety monitoring is planned after the injection?
• If the FDA has reported “serious adverse events” with unapproved exosome products, what is the clinic’s pathway for escalation if symptoms worsen?

Extra questions about BMAC (ankle cartilage defects)

• Is BMAC being offered as an adjunct to an established ankle procedure, and what extra benefit is expected beyond standard care alone?
• What does the iliac crest marrow harvest involve, and what are the specific donor‑site risks?
• Given that a systematic review found only 4 small talus studies with no randomised trials, what outcomes has this team seen at 2–5 years?

Extra questions about repeat steroid injections (hip/knee)

• How many injections have already been given in this joint, and how long did each one help (for example, 2–6 weeks versus longer)?
• What personal risk factors matter most here (for example, post‑injection glucose rise in diabetes) and is there a maximum number/frequency the clinician is comfortable with?
• Which of the 22 consensus recommendations (knee OA) is guiding dosing and spacing in this case?

A practical next step is matching these questions to the right clinician. Search MSK lists MSK specialists across the UK and can be filtered by region and specialty, helping identify clinicians who manage knee, hip, or ankle arthritis and who offer different injection options.

To prevent the decision drifting into “what’s newest” rather than “what fits”, a closing synthesis is useful: steroids tend to sit in the speed lane (short-term settling), BMAC is usually an adjunct with a procedure-and-harvest burden, and exosomes sit at the evidence/governance frontier where regulatory clarity matters as much as promised benefit. A short pause between consultation and an elective injection is often enough to confirm goals, risks, and the plan if the first choice does not deliver meaningful change.